Hücre İçi Sinyal İletimi

Mannino G, Russo C, Maugeri G, et al. Adult stem cell niches for tissue homeostasis. J Cell Physiol. 2022; 237(1): 239-257. doi: 10.1002/jcp.30562.

Son H, Moon A. Epithelial-mesenchymal Transition and Cell Invasion. Toxicol Res. 2010; 26(4): 245-252. doi: 10.5487/TR.2010.26.4.245.

Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119(6): 1420-1428. doi: 10.1172/JCI39104. Erratum in: J Clin Invest. 2010; 120(5): 1786.

Kim YS, Yi BR, Kim NH, et al. Role of the epithelial-mesenchymal transition and its effects on embryonic stem cells. Exp Mol Med. 2014; 46(8): e108. doi: 10.1038/emm.2014.44.

Thiery JP, Acloque H, Huang RY, et al. Epithelial-mesenchymal transitions in development and disease. Cell. 2009; 139(5): 871-890. doi: 10.1016/j.cell.2009.11.007.

Ismagulov G, Hamidi S, Sheng G. Epithelial-Mesenchymal Transition Drives Three-Dimensional Morphogenesis in Mammalian Early Development. Front Cell Dev Biol. 2021; 9: 639244. doi: 10.3389/fcell.2021.639244.

Posner BI, Laporte SA. Cellular signalling: Peptide hormones and growth factors. Prog Brain Res. 2010; 181: 1-16. doi: 10.1016/S0079-6123(08)81001-1.

Cooper GM. The Cell: A Molecular Approach. 2nd edition. Sunderland (MA): Sinauer Associates; 2000. Signaling Molecules and Their Receptors. (30/11/2022 tarihinde https://www.ncbi.nlm.nih.gov/books/NBK9924/ adresinden ulaşılmıştır).

Clause KC, Barker TH. Extracellular matrix signaling in morphogenesis and repair. Curr Opin Biotechnol. 2013; 24(5): 830-833. doi: 10.1016/j.copbio.2013.04.011.

Dengjel J, Akimov V, Blagoev B, et al. Signal transduction by growth factor receptors: signaling in an instant. Cell Cycle. 2007; 6(23): 2913-2916. doi: 10.4161/cc.6.23.5086.

Adjei AA, Hidalgo M. Intracellular signal transduction pathway proteins as targets for cancer therapy. J Clin Oncol. 2005; 23(23): 5386-5403. doi: 10.1200/JCO.2005.23.648.

Brown MD, Sacks DB. Adaptor Proteins. Offermanns S, Rosenthal W (Ed.) Encyclopedia of Molecular Pharmacology içinde. Berlin, Heidelberg: Springer; 2008. https://doi.org/10.1007/978-3-540-38918-7_265

Newton AC, Bootman MD, Scott JD. Second Messengers. Cold Spring Harb Perspect Biol. 2016; 8(8): a005926. doi: 10.1101/cshperspect.a005926.

Yan K, Gao LN, Cui YL, et al. The cyclic AMP signaling pathway: Exploring targets for successful drug discovery (Review). Mol Med Rep. 2016; 13(5): 3715-3723. doi: 10.3892/mmr.2016.5005.

Torres M, Forman HJ. Signal Transduction. Laurent GJ, Shapiro SD (Ed.) Encyclopedia of Respiratory Medicine içinde. Academic Press; 2006, p. 10-18.

van der Geer P, Hunter T, Lindberg RA. Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol. 1994; 10: 251-337. doi: 10.1146/annurev.cb.10.110194.001343.

Caicedo A. Paracrine and autocrine interactions in the human islet: more than meets the eye. Semin Cell Dev Biol. 2013; 24(1): 11-21. doi: 10.1016/j.semcdb.2012.09.007.

Scheel C, Eaton EN, Li SH, et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell. 2011; 145(6): 926-940. doi: 10.1016/j.cell.2011.04.029.

Xia P, Wadham C. Sphingosine 1-phosphate, a key mediator of the cytokine network: juxtacrine signaling. Cytokine Growth Factor Rev. 2011; 22(1): 45-53. doi: 10.1016/j.cytogfr.2010.09.004.

Gilbert SF. Developmental Biology. 6th edition. Sunderland (MA): Sinauer Associates; 2000. Juxtacrine Signaling. (30/11/2022 tarihinde https://www.ncbi.nlm.nih.gov/books/NBK10072/ adresinden ulaşılmıştır).

Müller P, Schier AF. Extracellular movement of signaling molecules. Dev Cell. 2011; 21(1): 145-158. doi: 10.1016/j.devcel.2011.06.001.

Valls PO, Esposito A. Signalling dynamics, cell decisions, and homeostatic control in health and disease. Curr Opin Cell Biol. 2022; 75: 102066. doi: 10.1016/j.ceb.2022.01.011.

Song D, Yang D, Powell CA, et al. Cell-cell communication: old mystery and new opportunity. Cell Biol Toxicol. 2019; 35(2): 89-93. doi: 10.1007/s10565-019-09470-y.

Mandoki JJ, Mendoza-Patiño N, Molina-Guarneros JA, et al. Hormone multifunctionalities: a theory of endocrine signaling, command and control. Prog Biophys Mol Biol. 2004; 86(3): 353-377. doi: 10.1016/j.pbiomolbio.2003.10.001.

Marques P, Skorupskaite K, Rozario KS, et al. Physiology of GnRH and Gonadotropin Secretion. [Updated 2022 Jan 5]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000- (30/11/2022 tarihinde https://www.ncbi.nlm.nih.gov/books/NBK279070/ adresinden ulaşılmıştır).

van der Geer P. Signal Transduction. Maloy S, Hughes K (Ed.) Brenner's Encyclopedia of Genetics (Second Edition) içinde. Academic Press; 2013, p. 436-439.

Enjalbert A, Le Pechon-Vallee C. Protein Kinases. Henry HL, Norman AW (Ed.) Encyclopedia of Hormones içinde. Academic Press; 2003, p. 277-285.

Hubbard SR, Miller WT. Receptor tyrosine kinases: mechanisms of activation and signaling. Curr Opin Cell Biol. 2007; 19(2): 117-123. doi: 10.1016/j.ceb.2007.02.010.

Heldin CH, Lu B, Evans R, et al. Signals and Receptors. Cold Spring Harb Perspect Biol. 2016; 8(4): a005900. doi: 10.1101/cshperspect.a005900.

Roy S, Vivoli Vega M, Harmer NJ. Carbohydrate Kinases: A Conserved Mechanism Across Differing Folds. Catalysts. 2019; 9(1): 29. https://doi.org/10.3390/catal9010029

Heath CM, Stahl PD, Barbieri MA. Lipid kinases play crucial and multiple roles in membrane trafficking and signaling. Histol Histopathol. 2003; 18(3): 989-998. doi: 10.14670/HH-18.989.

Shi Y. Serine/threonine phosphatases: mechanism through structure. Cell. 2009; 139(3): 468-484. doi: 10.1016/j.cell.2009.10.006.

Salon JA, Lodowski DT, Palczewski K. The significance of G protein-coupled receptor crystallography for drug discovery. Pharmacol Rev. 2011; 63(4): 901-937. doi: 10.1124/pr.110.003350.

Obot DN, Udom GJ, Udoh AE, et al. Advances in the molecular understanding of G protein-coupled receptors and their future therapeutic opportunities. Futur J Pharm Sci. 2021; 7: 194. https://doi.org/10.1186/s43094-021-00341-0

Hollmann MW, Strumper D, Herroeder S, et al. Receptors, G proteins, and their interactions. Anesthesiology. 2005; 103(5): 1066-1078. doi: 10.1097/00000542-200511000-00022.

Jang W, Adams CE, Liu H, et al. An inactive receptor-G protein complex maintains the dynamic range of agonist-induced signaling. Proc Natl Acad Sci USA. 2020; 117(48): 30755-30762. doi: 10.1073/pnas.2010801117.

Calebiro D, Koszegi Z, Lanoiselée Y, et al. G protein-coupled receptor-G protein interactions: a single-molecule perspective. Physiol Rev. 2021; 101(3): 857-906. doi: 10.1152/physrev.00021.2020.

Wettschureck N, Offermanns S. Mammalian G proteins and their cell type specific functions. Physiol Rev. 2005; 85(4): 1159-1204. doi: 10.1152/physrev.00003.2005.

Sassone-Corsi P. The cyclic AMP pathway. Cold Spring Harb Perspect Biol. 2012; 4(12): a011148. doi: 10.1101/cshperspect.a011148.

Sunahara RK, Dessauer CW, Gilman AG. Complexity and diversity of mammalian adenylyl cyclases. Annu Rev Pharmacol Toxicol. 1996; 36: 461-480. doi: 10.1146/annurev.pa.36.040196.002333.

Fabregat A, Sidiropoulos K, Viteri G, et al. Reactome pathway analysis: a high-performance in-memory approach. BMC Bioinformatics. 2017; 18(1): 142. doi: 10.1186/s12859-017-1559-2.

Kemp BE, Benjamini E, Krebs EG. Synthetic hexapeptide substrates and inhibitors of 3′:5′-cyclic AMP-dependent protein kinase. Proc Natl Acad Sci. 1976; 73: 1038–1042.

Scott JD. Cyclic nucleotide-dependent protein kinases. Pharmacology and Therapeutics. 1991; 50: 123–145.

Tasken K, Skalhegg BS, Solberg R, et al. Novel isozymes of cAMP-dependent protein kinase exist in human cells due to formation of RI alpha-RI beta heterodimeric complexes. Journal of Biological Chemistry. 1993; 268: 21276–21283.

Brushia RJ, Walsh DA. Phosphorylase kinase: the complexity of its regulation is reflected in the complexity of its structure. Front Biosci. 1999; 4: D618-41. doi: 10.2741/brushia.

Perianayagam MC, Madias NE, Pereira BJ, et al. CREB transcription factor modulates Bcl2 transcription in response to C5a in HL-60-derived neutrophils. Eur J Clin Invest. 2006; 36(5): 353-361. doi: 10.1111/j.1365-2362.2006.01637.x.

Mayer SI, Willars GB, Nishida E, et al. Elk-1, CREB, and MKP-1 regulate Egr-1 expression in gonadotropin-releasing hormone stimulated gonadotrophs. J Cell Biochem. 2008; 105(5): 1267-1278. doi: 10.1002/jcb.21927.

Sakamoto KM, Frank DA. CREB in the pathophysiology of cancer: implications for targeting transcription factors for cancer therapy. Clin Cancer Res. 2009; 15(8): 2583-2587. doi: 10.1158/1078-0432.CCR-08-1137. Erratum in: Clin Cancer Res. 2009; 15(10): 3643.

Liu Y, Bishop A, Witucki L, et al. Structural basis for selective inhibition of Src family kinases by PP1. Chem Biol. 1999; 6(9): 671-678. doi: 10.1016/s1074-5521(99)80118-5.

Huang FL, Glinsmann WH. Inactivation of rabbit muscle phosphorylase phosphatase by cyclic AMP-dependent kinas. Proc Natl Acad Sci U S A. 1975; 72(8):3004-3008. doi: 10.1073/pnas.72.8.3004.

Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem. 2007; 76: 481-511. doi: 10.1146/annurev.biochem.76.060305.150444.

Martin TF. Phosphoinositide lipids as signaling molecules: common themes for signal transduction, cytoskeletal regulation, and membrane trafficking. Annu Rev Cell Dev Biol. 1998; 14: 231-264. doi: 10.1146/annurev.cellbio.14.1.231.

Taylor SJ, Chae HZ, Rhee SG, et al. Activation of the beta 1 isozyme of phospholipase C by alpha subunits of the Gq class of G proteins. Nature. 1991; 350(6318): 516-518. doi: 10.1038/350516a0.

Berridge MJ. Inositol trisphosphate and diacylglycerol: two interacting second messengers. Annu Rev Biochem. 1987; 56: 159-193. doi: 10.1146/annurev.bi.56.070187.001111.

Crotty T, Cai J, Sakane F, et al. Diacylglycerol kinase delta regulates protein kinase C and epidermal growth factor receptor signaling. Proc Natl Acad Sci U S A. 2006; 103(42): 15485-15490. doi: 10.1073/pnas.0604104103.

Ueda Y, Hirai Si, Osada Si, et al. Protein kinase C activates the MEK-ERK pathway in a manner independent of Ras and dependent on Raf. J Biol Chem. 1996; 271(38): 23512-23519. doi: 10.1074/jbc.271.38.23512.

Foskett JK, White C, Cheung KH, et al. Inositol trisphosphate receptor Ca2+ release channels. Physiol Rev. 2007; 87(2): 593-658. doi: 10.1152/physrev.00035.2006.

New DC, Wu K, Kwok AW, et al. G protein-coupled receptor-induced Akt activity in cellular proliferation and apoptosis. FEBS J. 2007; 274(23): 6025-6036. doi: 10.1111/j.1742-4658.2007.06116.x.

Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell. 1990; 61(2): 203-212. doi: 10.1016/0092-8674(90)90801-k.

Dawson JP, Berger MB, Lin CC, et al. Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface. Mol Cell Biol. 2005; 25(17): 7734-7742. doi: 10.1128/MCB.25.17.7734-7742.2005.

Luo LY, Hahn WC. Oncogenic Signaling Adaptor Proteins. J Genet Genomics. 2015; 42(10): 521-529. doi: 10.1016/j.jgg.2015.09.001.

Pawson T. Dynamic control of signaling by modular adaptor proteins. Curr Opin Cell Biol. 2007; 19(2): 112-116. doi: 10.1016/j.ceb.2007.02.013.

Yaffe MB. Phosphotyrosine-binding domains in signal transduction. Nat Rev Mol Cell Biol. 2002; 3(3): 177-186. doi: 10.1038/nrm759.

Lemmon MA, Ferguson KM, Abrams CS. Pleckstrin homology domains and the cytoskeleton. FEBS Lett. 2002; 513(1): 71-76. doi: 10.1016/s0014-5793(01)03243-4.

Abankwa D, Gorfe AA, Inder K, et al. Ras membrane orientation and nanodomain localization generate isoform diversity. Proc Natl Acad Sci U S A. 2010; 107(3): 1130-1135. doi: 10.1073/pnas.0903907107.

Simanshu DK, Nissley DV, McCormick F. RAS Proteins and Their Regulators in Human Disease. Cell. 2017; 170(1): 17-33. doi: 10.1016/j.cell.2017.06.009.

Buday L, Egan SE, Rodriguez Viciana P, et al. A complex of Grb2 adaptor protein, Sos exchange factor, and a 36-kDa membrane-bound tyrosine phosphoprotein is implicated in ras activation in T cells. J Biol Chem. 1994; 269(12): 9019-9023.

Skolnik EY, Batzer A, Li N, et al. The function of GRB2 in linking the insulin receptor to Ras signaling pathways. Science. 1993; 260(5116): 1953-1955. doi: 10.1126/science.8316835.

Simon JA, Schreiber SL. Grb2 SH3 binding to peptides from Sos: evaluation of a general model for SH3-ligand interactions. Chem Biol. 1995; 2(1): 53-60. doi: 10.1016/1074-5521(95)90080-2.

Nan X, Tamgüney TM, Collisson EA, et al. Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway. Proc Natl Acad Sci U S A. 2015; 112(26): 7996-8001. doi: 10.1073/pnas.1509123112.

Moodie SA, Willumsen BM, Weber MJ, et al. Complexes of Ras.GTP with Raf-1 and mitogen-activated protein kinase kinase. Science. 1993; 260(5114): 1658-1661. doi: 10.1126/science.8503013.

Vojtek AB, Hollenberg SM, Cooper JA. Mammalian Ras interacts directly with the serine/threonine kinase Raf. Cell. 1993; 74(1): 205-214. doi: 10.1016/0092-8674(93)90307-c.

Dent P, Haser W, Haystead TA, et al. Activation of mitogen-activated protein kinase kinase by v-Raf in NIH 3T3 cells and in vitro. Science. 1992; 257(5075): 1404-1407. doi: 10.1126/science.1326789.

Zhang W, Liu HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 2002; 12(1): 9-18. doi: 10.1038/sj.cr.7290105.

Geltz NR, Augustine JA. The p85 and p110 subunits of phosphatidylinositol 3-kinase-alpha are substrates, in vitro, for a constitutively associated protein tyrosine kinase in platelets. Blood. 1998; 91(3): 930-939.

McGlade CJ, Ellis C, Reedijk M, et al. SH2 domains of the p85 alpha subunit of phosphatidylinositol 3-kinase regulate binding to growth factor receptors. Mol Cell Biol. 1992; 12(3): 991-997. doi: 10.1128/mcb.12.3.991-997.1992.

Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR Signaling in Cancer. Front Oncol. 2014; 4: 64. doi: 10.3389/fonc.2014.00064.

Paplomata E, O’Regan R. The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. Ther Adv Med Oncol. 2014; 6(4):154–166.

Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012; 149(2): 274-293. doi: 10.1016/j.cell.2012.03.017.

Maehama T, Dixon JE. PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol. 1999; 9(4): 125-128. doi: 10.1016/s0962-8924(99)01519-6.

Scheid MP, Parsons M, Woodgett JR. Phosphoinositide-dependent phosphorylation of PDK1 regulates nuclear translocation. Mol Cell Biol. 2005; 25(6): 2347-2363. doi: 10.1128/MCB.25.6.2347-2363.2005.

Alessi DR, James SR, Downes CP, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol. 1997; 7(4): 261-269. doi: 10.1016/s0960-9822(06)00122-9.

Cai SL, Tee AR, Short JD, et al. Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning. J Cell Biol. 2006; 173(2): 279-289. doi: 10.1083/jcb.200507119.

Hansmann P, Brückner A, Kiontke S, et al. Structure of the TSC2 GAP Domain: Mechanistic Insight into Catalysis and Pathogenic Mutations. Structure. 2020; 28(8): 933-942.e4. doi: 10.1016/j.str.2020.05.008.

Zhang Y, Gao X, Saucedo LJ, et al. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol. 2003; 5(6): 578-581. doi: 10.1038/ncb999.

Yang H, Jiang X, Li B, et al. Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40. Nature. 2017; 552(7685): 368-373. doi: 10.1038/nature25023.

Yip CK, Murata K, Walz T, et al. Structure of the human mTOR complex I and its implications for rapamycin inhibition. Mol Cell. 2010; 38(5): 768-774. doi: 10.1016/j.molcel.2010.05.017.

Stuttfeld E, Aylett CH, Imseng S, et al. Architecture of the human mTORC2 core complex. Elife. 2018; 7: e33101. doi: 10.7554/eLife.33101.

Böhm R, Imseng S, Jakob RP, et al. The dynamic mechanism of 4E-BP1 recognition and phosphorylation by mTORC1. Mol Cell. 2021; 81(11): 2403-2416.e5. doi: 10.1016/j.molcel.2021.03.031.

Gingras AC, Gygi SP, Raught B, et al. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev. 1999; 13(11): 1422-1437. doi: 10.1101/gad.13.11.1422.

Holz MK, Ballif BA, Gygi SP, et al. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell. 2005; 123(4): 569-580. doi: 10.1016/j.cell.2005.10.024.

Hong F, Larrea MD, Doughty C, et al. mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. Mol Cell. 2008; 30(6): 701-711. doi: 10.1016/j.molcel.2008.04.027.

Schmid E, Gu S, Yang W, et al. Serum- and glucocorticoid-inducible kinase SGK1 regulates reorganization of actin cytoskeleton in mast cells upon degranulation. Am J Physiol Cell Physiol. 2013; 304(1): C49-55. doi: 10.1152/ajpcell.00179.2012.

Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004; 20: 781-810. doi: 10.1146/annurev.cellbio.20.010403.113126.

Ikeya M, Lee SM, Johnson JE, et al. Wnt signalling required for expansion of neural crest and CNS progenitors. Nature. 1997; 389(6654): 966-970. doi: 10.1038/40146.

Barrow JR, Thomas KR, Boussadia-Zahui O, et al. Ectodermal Wnt3/beta-catenin signaling is required for the establishment and maintenance of the apical ectodermal ridge. Genes Dev. 2003; 17(3): 394-409. doi: 10.1101/gad.1044903.

MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009; 17: 9-26. https://doi.org/10.1016/j.devcel.2009.06.016.

Wang Z, Zhao T, Zhang S, et al. The Wnt signaling pathway in tumorigenesis, pharmacological targets, and drug development for cancer therapy. Biomark Res. 2021; 9: 68. https://doi.org/10.1186/s40364-021-00323-7.

Van Camp JK, Beckers S, Zegers D, et al. Wnt signaling and the control of human stem cell fate. Stem Cell Rev Rep. 2014; 10: 207-229. https://doi.org/10.1007/s12015-013-9486-8.

Wu Y, Ginther C, Kim J, et al. Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells. Mol Cancer Res. 2012; 10(12): 1597-1606. doi: 10.1158/1541-7786.MCR-12-0155-T.

Kaur N, Chettiar S, Rathod S, et al. Wnt3a mediated activation of Wnt/β-catenin signaling promotes tumor progression in glioblastoma. Mol Cell Neurosci. 2013; 54: 44-57. doi: 10.1016/j.mcn.2013.01.001.

Oloumi A, Syam S, Dedhar S. Modulation of Wnt3a-mediated nuclear beta-catenin accumulation and activation by integrin-linked kinase in mammalian cells. Oncogene. 2006; 25(59): 7747-7757. doi: 10.1038/sj.onc.1209752.

Huang X, Zhu H, Gao Z, et al. Wnt7a activates canonical Wnt signaling, promotes bladder cancer cell invasion, and is suppressed by miR-370-3p. J Biol Chem. 2018; 293(18): 6693-6706. doi: 10.1074/jbc.RA118.001689.

L'episcopo F, Serapide MF, Tirolo C, et al. A Wnt1 regulated Frizzled-1/β-Catenin signaling pathway as a candidate regulatory circuit controlling mesencephalic dopaminergic neuron-astrocyte crosstalk: Therapeutical relevance for neuron survival and neuroprotection. Mol Neurodegener. 2011; 6: 49. doi: 10.1186/1750-1326-6-49.

Martineau X, Abed É, Martel-Pelletier J, et al. Alteration of Wnt5a expression and of the non-canonical Wnt/PCP and Wnt/PKC-Ca2+ pathways in human osteoarthritis osteoblasts. PLoS One. 2017; 12(8): e0180711. doi: 10.1371/journal.pone.0180711.

Pandur P, Läsche M, Eisenberg LM, et al. Wnt-11 activation of a non-canonical Wnt signalling pathway is required for cardiogenesis. Nature. 2002; 418(6898): 636-641. doi: 10.1038/nature00921.

Huang HC, Klein PS. The Frizzled family: receptors for multiple signal transduction pathways. Genome Biol. 2004; 5(7): 234. doi: 10.1186/gb-2004-5-7-234.

Dijksterhuis JP, Baljinnyam B, Stanger K, et al. Systematic mapping of WNT-FZD protein interactions reveals functional selectivity by distinct WNT-FZD pairs. J Biol Chem. 2015; 290(11): 6789-6798. doi: 10.1074/jbc.M114.612648.

von Maltzahn J, Bentzinger CF, Rudnicki MA. Wnt7a-Fzd7 signalling directly activates the Akt/mTOR anabolic growth pathway in skeletal muscle. Nat Cell Biol. 2011; 14(2): 186-191. doi: 10.1038/ncb2404.

Hayat R, Manzoor M, Hussain A. Wnt signaling pathway: A comprehensive review. Cell Biol Int. 2022; 46(6): 863-877. doi: 10.1002/cbin.11797.

Liu J, Xiao Q, Xiao J, et al. Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther. 2022; 7(1): 3. doi: 10.1038/s41392-021-00762-6.

Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006; 127(3): 469-480. doi: 10.1016/j.cell.2006.10.018.

Wen X, Wu Y, Awadasseid A, et al. New Advances in Canonical Wnt/β-Catenin Signaling in Cancer. Cancer Manag Res. 2020; 12: 6987-6998. doi: 10.2147/CMAR.S258645.

Katoh M. Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review). Int J Oncol. 2017; 51(5): 1357-1369. doi: 10.3892/ijo.2017.4129.

Corda G, Sala A. Non-canonical WNT/PCP signalling in cancer: Fzd6 takes centre stage. Oncogenesis. 2017; 6(7): e364. doi: 10.1038/oncsis.2017.69.

Mannino G, Russo C, Maugeri G, et al. Adult stem cell niches for tissue homeostasis. J Cell Physiol. 2022; 237(1): 239-257. doi: 10.1002/jcp.30562.

Son H, Moon A. Epithelial-mesenchymal Transition and Cell Invasion. Toxicol Res. 2010; 26(4): 245-252. doi: 10.5487/TR.2010.26.4.245.

Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119(6): 1420-1428. doi: 10.1172/JCI39104. Erratum in: J Clin Invest. 2010; 120(5): 1786.

Kim YS, Yi BR, Kim NH, et al. Role of the epithelial-mesenchymal transition and its effects on embryonic stem cells. Exp Mol Med. 2014; 46(8): e108. doi: 10.1038/emm.2014.44.

Thiery JP, Acloque H, Huang RY, et al. Epithelial-mesenchymal transitions in development and disease. Cell. 2009; 139(5): 871-890. doi: 10.1016/j.cell.2009.11.007.

Ismagulov G, Hamidi S, Sheng G. Epithelial-Mesenchymal Transition Drives Three-Dimensional Morphogenesis in Mammalian Early Development. Front Cell Dev Biol. 2021; 9: 639244. doi: 10.3389/fcell.2021.639244.

Posner BI, Laporte SA. Cellular signalling: Peptide hormones and growth factors. Prog Brain Res. 2010; 181: 1-16. doi: 10.1016/S0079-6123(08)81001-1.

Cooper GM. The Cell: A Molecular Approach. 2nd edition. Sunderland (MA): Sinauer Associates; 2000. Signaling Molecules and Their Receptors. (30/11/2022 tarihinde https://www.ncbi.nlm.nih.gov/books/NBK9924/ adresinden ulaşılmıştır).

Clause KC, Barker TH. Extracellular matrix signaling in morphogenesis and repair. Curr Opin Biotechnol. 2013; 24(5): 830-833. doi: 10.1016/j.copbio.2013.04.011.

Dengjel J, Akimov V, Blagoev B, et al. Signal transduction by growth factor receptors: signaling in an instant. Cell Cycle. 2007; 6(23): 2913-2916. doi: 10.4161/cc.6.23.5086.

Adjei AA, Hidalgo M. Intracellular signal transduction pathway proteins as targets for cancer therapy. J Clin Oncol. 2005; 23(23): 5386-5403. doi: 10.1200/JCO.2005.23.648.

Brown MD, Sacks DB. Adaptor Proteins. Offermanns S, Rosenthal W (Ed.) Encyclopedia of Molecular Pharmacology içinde. Berlin, Heidelberg: Springer; 2008. https://doi.org/10.1007/978-3-540-38918-7_265

Newton AC, Bootman MD, Scott JD. Second Messengers. Cold Spring Harb Perspect Biol. 2016; 8(8): a005926. doi: 10.1101/cshperspect.a005926.

Yan K, Gao LN, Cui YL, et al. The cyclic AMP signaling pathway: Exploring targets for successful drug discovery (Review). Mol Med Rep. 2016; 13(5): 3715-3723. doi: 10.3892/mmr.2016.5005.

Torres M, Forman HJ. Signal Transduction. Laurent GJ, Shapiro SD (Ed.) Encyclopedia of Respiratory Medicine içinde. Academic Press; 2006, p. 10-18.

van der Geer P, Hunter T, Lindberg RA. Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol. 1994; 10: 251-337. doi: 10.1146/annurev.cb.10.110194.001343.

Caicedo A. Paracrine and autocrine interactions in the human islet: more than meets the eye. Semin Cell Dev Biol. 2013; 24(1): 11-21. doi: 10.1016/j.semcdb.2012.09.007.

Scheel C, Eaton EN, Li SH, et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell. 2011; 145(6): 926-940. doi: 10.1016/j.cell.2011.04.029.

Xia P, Wadham C. Sphingosine 1-phosphate, a key mediator of the cytokine network: juxtacrine signaling. Cytokine Growth Factor Rev. 2011; 22(1): 45-53. doi: 10.1016/j.cytogfr.2010.09.004.

Gilbert SF. Developmental Biology. 6th edition. Sunderland (MA): Sinauer Associates; 2000. Juxtacrine Signaling. (30/11/2022 tarihinde https://www.ncbi.nlm.nih.gov/books/NBK10072/ adresinden ulaşılmıştır).

Müller P, Schier AF. Extracellular movement of signaling molecules. Dev Cell. 2011; 21(1): 145-158. doi: 10.1016/j.devcel.2011.06.001.

Valls PO, Esposito A. Signalling dynamics, cell decisions, and homeostatic control in health and disease. Curr Opin Cell Biol. 2022; 75: 102066. doi: 10.1016/j.ceb.2022.01.011.

Song D, Yang D, Powell CA, et al. Cell-cell communication: old mystery and new opportunity. Cell Biol Toxicol. 2019; 35(2): 89-93. doi: 10.1007/s10565-019-09470-y.

Mandoki JJ, Mendoza-Patiño N, Molina-Guarneros JA, et al. Hormone multifunctionalities: a theory of endocrine signaling, command and control. Prog Biophys Mol Biol. 2004; 86(3): 353-377. doi: 10.1016/j.pbiomolbio.2003.10.001.

Marques P, Skorupskaite K, Rozario KS, et al. Physiology of GnRH and Gonadotropin Secretion. [Updated 2022 Jan 5]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000- (30/11/2022 tarihinde https://www.ncbi.nlm.nih.gov/books/NBK279070/ adresinden ulaşılmıştır).

van der Geer P. Signal Transduction. Maloy S, Hughes K (Ed.) Brenner's Encyclopedia of Genetics (Second Edition) içinde. Academic Press; 2013, p. 436-439.

Enjalbert A, Le Pechon-Vallee C. Protein Kinases. Henry HL, Norman AW (Ed.) Encyclopedia of Hormones içinde. Academic Press; 2003, p. 277-285.

Hubbard SR, Miller WT. Receptor tyrosine kinases: mechanisms of activation and signaling. Curr Opin Cell Biol. 2007; 19(2): 117-123. doi: 10.1016/j.ceb.2007.02.010.

Heldin CH, Lu B, Evans R, et al. Signals and Receptors. Cold Spring Harb Perspect Biol. 2016; 8(4): a005900. doi: 10.1101/cshperspect.a005900.

Roy S, Vivoli Vega M, Harmer NJ. Carbohydrate Kinases: A Conserved Mechanism Across Differing Folds. Catalysts. 2019; 9(1): 29. https://doi.org/10.3390/catal9010029

Heath CM, Stahl PD, Barbieri MA. Lipid kinases play crucial and multiple roles in membrane trafficking and signaling. Histol Histopathol. 2003; 18(3): 989-998. doi: 10.14670/HH-18.989.

Shi Y. Serine/threonine phosphatases: mechanism through structure. Cell. 2009; 139(3): 468-484. doi: 10.1016/j.cell.2009.10.006.

Salon JA, Lodowski DT, Palczewski K. The significance of G protein-coupled receptor crystallography for drug discovery. Pharmacol Rev. 2011; 63(4): 901-937. doi: 10.1124/pr.110.003350.

Obot DN, Udom GJ, Udoh AE, et al. Advances in the molecular understanding of G protein-coupled receptors and their future therapeutic opportunities. Futur J Pharm Sci. 2021; 7: 194. https://doi.org/10.1186/s43094-021-00341-0

Hollmann MW, Strumper D, Herroeder S, et al. Receptors, G proteins, and their interactions. Anesthesiology. 2005; 103(5): 1066-1078. doi: 10.1097/00000542-200511000-00022.

Jang W, Adams CE, Liu H, et al. An inactive receptor-G protein complex maintains the dynamic range of agonist-induced signaling. Proc Natl Acad Sci USA. 2020; 117(48): 30755-30762. doi: 10.1073/pnas.2010801117.

Calebiro D, Koszegi Z, Lanoiselée Y, et al. G protein-coupled receptor-G protein interactions: a single-molecule perspective. Physiol Rev. 2021; 101(3): 857-906. doi: 10.1152/physrev.00021.2020.

Wettschureck N, Offermanns S. Mammalian G proteins and their cell type specific functions. Physiol Rev. 2005; 85(4): 1159-1204. doi: 10.1152/physrev.00003.2005.

Sassone-Corsi P. The cyclic AMP pathway. Cold Spring Harb Perspect Biol. 2012; 4(12): a011148. doi: 10.1101/cshperspect.a011148.

Sunahara RK, Dessauer CW, Gilman AG. Complexity and diversity of mammalian adenylyl cyclases. Annu Rev Pharmacol Toxicol. 1996; 36: 461-480. doi: 10.1146/annurev.pa.36.040196.002333.

Fabregat A, Sidiropoulos K, Viteri G, et al. Reactome pathway analysis: a high-performance in-memory approach. BMC Bioinformatics. 2017; 18(1): 142. doi: 10.1186/s12859-017-1559-2.

Kemp BE, Benjamini E, Krebs EG. Synthetic hexapeptide substrates and inhibitors of 3′:5′-cyclic AMP-dependent protein kinase. Proc Natl Acad Sci. 1976; 73: 1038–1042.

Scott JD. Cyclic nucleotide-dependent protein kinases. Pharmacology and Therapeutics. 1991; 50: 123–145.

Tasken K, Skalhegg BS, Solberg R, et al. Novel isozymes of cAMP-dependent protein kinase exist in human cells due to formation of RI alpha-RI beta heterodimeric complexes. Journal of Biological Chemistry. 1993; 268: 21276–21283.

Brushia RJ, Walsh DA. Phosphorylase kinase: the complexity of its regulation is reflected in the complexity of its structure. Front Biosci. 1999; 4: D618-41. doi: 10.2741/brushia.

Perianayagam MC, Madias NE, Pereira BJ, et al. CREB transcription factor modulates Bcl2 transcription in response to C5a in HL-60-derived neutrophils. Eur J Clin Invest. 2006; 36(5): 353-361. doi: 10.1111/j.1365-2362.2006.01637.x.

Mayer SI, Willars GB, Nishida E, et al. Elk-1, CREB, and MKP-1 regulate Egr-1 expression in gonadotropin-releasing hormone stimulated gonadotrophs. J Cell Biochem. 2008; 105(5): 1267-1278. doi: 10.1002/jcb.21927.

Sakamoto KM, Frank DA. CREB in the pathophysiology of cancer: implications for targeting transcription factors for cancer therapy. Clin Cancer Res. 2009; 15(8): 2583-2587. doi: 10.1158/1078-0432.CCR-08-1137. Erratum in: Clin Cancer Res. 2009; 15(10): 3643.

Liu Y, Bishop A, Witucki L, et al. Structural basis for selective inhibition of Src family kinases by PP1. Chem Biol. 1999; 6(9): 671-678. doi: 10.1016/s1074-5521(99)80118-5.

Huang FL, Glinsmann WH. Inactivation of rabbit muscle phosphorylase phosphatase by cyclic AMP-dependent kinas. Proc Natl Acad Sci U S A. 1975; 72(8):3004-3008. doi: 10.1073/pnas.72.8.3004.

Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem. 2007; 76: 481-511. doi: 10.1146/annurev.biochem.76.060305.150444.

Martin TF. Phosphoinositide lipids as signaling molecules: common themes for signal transduction, cytoskeletal regulation, and membrane trafficking. Annu Rev Cell Dev Biol. 1998; 14: 231-264. doi: 10.1146/annurev.cellbio.14.1.231.

Taylor SJ, Chae HZ, Rhee SG, et al. Activation of the beta 1 isozyme of phospholipase C by alpha subunits of the Gq class of G proteins. Nature. 1991; 350(6318): 516-518. doi: 10.1038/350516a0.

Berridge MJ. Inositol trisphosphate and diacylglycerol: two interacting second messengers. Annu Rev Biochem. 1987; 56: 159-193. doi: 10.1146/annurev.bi.56.070187.001111.

Crotty T, Cai J, Sakane F, et al. Diacylglycerol kinase delta regulates protein kinase C and epidermal growth factor receptor signaling. Proc Natl Acad Sci U S A. 2006; 103(42): 15485-15490. doi: 10.1073/pnas.0604104103.

Ueda Y, Hirai Si, Osada Si, et al. Protein kinase C activates the MEK-ERK pathway in a manner independent of Ras and dependent on Raf. J Biol Chem. 1996; 271(38): 23512-23519. doi: 10.1074/jbc.271.38.23512.

Foskett JK, White C, Cheung KH, et al. Inositol trisphosphate receptor Ca2+ release channels. Physiol Rev. 2007; 87(2): 593-658. doi: 10.1152/physrev.00035.2006.

New DC, Wu K, Kwok AW, et al. G protein-coupled receptor-induced Akt activity in cellular proliferation and apoptosis. FEBS J. 2007; 274(23): 6025-6036. doi: 10.1111/j.1742-4658.2007.06116.x.

Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell. 1990; 61(2): 203-212. doi: 10.1016/0092-8674(90)90801-k.

Dawson JP, Berger MB, Lin CC, et al. Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface. Mol Cell Biol. 2005; 25(17): 7734-7742. doi: 10.1128/MCB.25.17.7734-7742.2005.

Luo LY, Hahn WC. Oncogenic Signaling Adaptor Proteins. J Genet Genomics. 2015; 42(10): 521-529. doi: 10.1016/j.jgg.2015.09.001.

Pawson T. Dynamic control of signaling by modular adaptor proteins. Curr Opin Cell Biol. 2007; 19(2): 112-116. doi: 10.1016/j.ceb.2007.02.013.

Yaffe MB. Phosphotyrosine-binding domains in signal transduction. Nat Rev Mol Cell Biol. 2002; 3(3): 177-186. doi: 10.1038/nrm759.

Lemmon MA, Ferguson KM, Abrams CS. Pleckstrin homology domains and the cytoskeleton. FEBS Lett. 2002; 513(1): 71-76. doi: 10.1016/s0014-5793(01)03243-4.

Abankwa D, Gorfe AA, Inder K, et al. Ras membrane orientation and nanodomain localization generate isoform diversity. Proc Natl Acad Sci U S A. 2010; 107(3): 1130-1135. doi: 10.1073/pnas.0903907107.

Simanshu DK, Nissley DV, McCormick F. RAS Proteins and Their Regulators in Human Disease. Cell. 2017; 170(1): 17-33. doi: 10.1016/j.cell.2017.06.009.

Buday L, Egan SE, Rodriguez Viciana P, et al. A complex of Grb2 adaptor protein, Sos exchange factor, and a 36-kDa membrane-bound tyrosine phosphoprotein is implicated in ras activation in T cells. J Biol Chem. 1994; 269(12): 9019-9023.

Skolnik EY, Batzer A, Li N, et al. The function of GRB2 in linking the insulin receptor to Ras signaling pathways. Science. 1993; 260(5116): 1953-1955. doi: 10.1126/science.8316835.

Simon JA, Schreiber SL. Grb2 SH3 binding to peptides from Sos: evaluation of a general model for SH3-ligand interactions. Chem Biol. 1995; 2(1): 53-60. doi: 10.1016/1074-5521(95)90080-2.

Nan X, Tamgüney TM, Collisson EA, et al. Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway. Proc Natl Acad Sci U S A. 2015; 112(26): 7996-8001. doi: 10.1073/pnas.1509123112.

Moodie SA, Willumsen BM, Weber MJ, et al. Complexes of Ras.GTP with Raf-1 and mitogen-activated protein kinase kinase. Science. 1993; 260(5114): 1658-1661. doi: 10.1126/science.8503013.

Vojtek AB, Hollenberg SM, Cooper JA. Mammalian Ras interacts directly with the serine/threonine kinase Raf. Cell. 1993; 74(1): 205-214. doi: 10.1016/0092-8674(93)90307-c.

Dent P, Haser W, Haystead TA, et al. Activation of mitogen-activated protein kinase kinase by v-Raf in NIH 3T3 cells and in vitro. Science. 1992; 257(5075): 1404-1407. doi: 10.1126/science.1326789.

Zhang W, Liu HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 2002; 12(1): 9-18. doi: 10.1038/sj.cr.7290105.

Geltz NR, Augustine JA. The p85 and p110 subunits of phosphatidylinositol 3-kinase-alpha are substrates, in vitro, for a constitutively associated protein tyrosine kinase in platelets. Blood. 1998; 91(3): 930-939.

McGlade CJ, Ellis C, Reedijk M, et al. SH2 domains of the p85 alpha subunit of phosphatidylinositol 3-kinase regulate binding to growth factor receptors. Mol Cell Biol. 1992; 12(3): 991-997. doi: 10.1128/mcb.12.3.991-997.1992.

Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR Signaling in Cancer. Front Oncol. 2014; 4: 64. doi: 10.3389/fonc.2014.00064.

Paplomata E, O’Regan R. The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. Ther Adv Med Oncol. 2014; 6(4):154–166.

Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012; 149(2): 274-293. doi: 10.1016/j.cell.2012.03.017.

Maehama T, Dixon JE. PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol. 1999; 9(4): 125-128. doi: 10.1016/s0962-8924(99)01519-6.

Scheid MP, Parsons M, Woodgett JR. Phosphoinositide-dependent phosphorylation of PDK1 regulates nuclear translocation. Mol Cell Biol. 2005; 25(6): 2347-2363. doi: 10.1128/MCB.25.6.2347-2363.2005.

Alessi DR, James SR, Downes CP, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol. 1997; 7(4): 261-269. doi: 10.1016/s0960-9822(06)00122-9.

Cai SL, Tee AR, Short JD, et al. Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning. J Cell Biol. 2006; 173(2): 279-289. doi: 10.1083/jcb.200507119.

Hansmann P, Brückner A, Kiontke S, et al. Structure of the TSC2 GAP Domain: Mechanistic Insight into Catalysis and Pathogenic Mutations. Structure. 2020; 28(8): 933-942.e4. doi: 10.1016/j.str.2020.05.008.

Zhang Y, Gao X, Saucedo LJ, et al. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol. 2003; 5(6): 578-581. doi: 10.1038/ncb999.

Yang H, Jiang X, Li B, et al. Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40. Nature. 2017; 552(7685): 368-373. doi: 10.1038/nature25023.

Yip CK, Murata K, Walz T, et al. Structure of the human mTOR complex I and its implications for rapamycin inhibition. Mol Cell. 2010; 38(5): 768-774. doi: 10.1016/j.molcel.2010.05.017.

Stuttfeld E, Aylett CH, Imseng S, et al. Architecture of the human mTORC2 core complex. Elife. 2018; 7: e33101. doi: 10.7554/eLife.33101.

Böhm R, Imseng S, Jakob RP, et al. The dynamic mechanism of 4E-BP1 recognition and phosphorylation by mTORC1. Mol Cell. 2021; 81(11): 2403-2416.e5. doi: 10.1016/j.molcel.2021.03.031.

Gingras AC, Gygi SP, Raught B, et al. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev. 1999; 13(11): 1422-1437. doi: 10.1101/gad.13.11.1422.

Holz MK, Ballif BA, Gygi SP, et al. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell. 2005; 123(4): 569-580. doi: 10.1016/j.cell.2005.10.024.

Hong F, Larrea MD, Doughty C, et al. mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. Mol Cell. 2008; 30(6): 701-711. doi: 10.1016/j.molcel.2008.04.027.

Schmid E, Gu S, Yang W, et al. Serum- and glucocorticoid-inducible kinase SGK1 regulates reorganization of actin cytoskeleton in mast cells upon degranulation. Am J Physiol Cell Physiol. 2013; 304(1): C49-55. doi: 10.1152/ajpcell.00179.2012.

Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004; 20: 781-810. doi: 10.1146/annurev.cellbio.20.010403.113126.

Ikeya M, Lee SM, Johnson JE, et al. Wnt signalling required for expansion of neural crest and CNS progenitors. Nature. 1997; 389(6654): 966-970. doi: 10.1038/40146.

Barrow JR, Thomas KR, Boussadia-Zahui O, et al. Ectodermal Wnt3/beta-catenin signaling is required for the establishment and maintenance of the apical ectodermal ridge. Genes Dev. 2003; 17(3): 394-409. doi: 10.1101/gad.1044903.

MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009; 17: 9-26. https://doi.org/10.1016/j.devcel.2009.06.016.

Wang Z, Zhao T, Zhang S, et al. The Wnt signaling pathway in tumorigenesis, pharmacological targets, and drug development for cancer therapy. Biomark Res. 2021; 9: 68. https://doi.org/10.1186/s40364-021-00323-7.

Van Camp JK, Beckers S, Zegers D, et al. Wnt signaling and the control of human stem cell fate. Stem Cell Rev Rep. 2014; 10: 207-229. https://doi.org/10.1007/s12015-013-9486-8.

Wu Y, Ginther C, Kim J, et al. Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells. Mol Cancer Res. 2012; 10(12): 1597-1606. doi: 10.1158/1541-7786.MCR-12-0155-T.

Kaur N, Chettiar S, Rathod S, et al. Wnt3a mediated activation of Wnt/β-catenin signaling promotes tumor progression in glioblastoma. Mol Cell Neurosci. 2013; 54: 44-57. doi: 10.1016/j.mcn.2013.01.001.

Oloumi A, Syam S, Dedhar S. Modulation of Wnt3a-mediated nuclear beta-catenin accumulation and activation by integrin-linked kinase in mammalian cells. Oncogene. 2006; 25(59): 7747-7757. doi: 10.1038/sj.onc.1209752.

Huang X, Zhu H, Gao Z, et al. Wnt7a activates canonical Wnt signaling, promotes bladder cancer cell invasion, and is suppressed by miR-370-3p. J Biol Chem. 2018; 293(18): 6693-6706. doi: 10.1074/jbc.RA118.001689.

L'episcopo F, Serapide MF, Tirolo C, et al. A Wnt1 regulated Frizzled-1/β-Catenin signaling pathway as a candidate regulatory circuit controlling mesencephalic dopaminergic neuron-astrocyte crosstalk: Therapeutical relevance for neuron survival and neuroprotection. Mol Neurodegener. 2011; 6: 49. doi: 10.1186/1750-1326-6-49.

Martineau X, Abed É, Martel-Pelletier J, et al. Alteration of Wnt5a expression and of the non-canonical Wnt/PCP and Wnt/PKC-Ca2+ pathways in human osteoarthritis osteoblasts. PLoS One. 2017; 12(8): e0180711. doi: 10.1371/journal.pone.0180711.

Pandur P, Läsche M, Eisenberg LM, et al. Wnt-11 activation of a non-canonical Wnt signalling pathway is required for cardiogenesis. Nature. 2002; 418(6898): 636-641. doi: 10.1038/nature00921.

Huang HC, Klein PS. The Frizzled family: receptors for multiple signal transduction pathways. Genome Biol. 2004; 5(7): 234. doi: 10.1186/gb-2004-5-7-234.

Dijksterhuis JP, Baljinnyam B, Stanger K, et al. Systematic mapping of WNT-FZD protein interactions reveals functional selectivity by distinct WNT-FZD pairs. J Biol Chem. 2015; 290(11): 6789-6798. doi: 10.1074/jbc.M114.612648.

von Maltzahn J, Bentzinger CF, Rudnicki MA. Wnt7a-Fzd7 signalling directly activates the Akt/mTOR anabolic growth pathway in skeletal muscle. Nat Cell Biol. 2011; 14(2): 186-191. doi: 10.1038/ncb2404.

Hayat R, Manzoor M, Hussain A. Wnt signaling pathway: A comprehensive review. Cell Biol Int. 2022; 46(6): 863-877. doi: 10.1002/cbin.11797.

Liu J, Xiao Q, Xiao J, et al. Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther. 2022; 7(1): 3. doi: 10.1038/s41392-021-00762-6.

Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006; 127(3): 469-480. doi: 10.1016/j.cell.2006.10.018.

Wen X, Wu Y, Awadasseid A, et al. New Advances in Canonical Wnt/β-Catenin Signaling in Cancer. Cancer Manag Res. 2020; 12: 6987-6998. doi: 10.2147/CMAR.S258645.

Katoh M. Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review). Int J Oncol. 2017; 51(5): 1357-1369. doi: 10.3892/ijo.2017.4129.

Corda G, Sala A. Non-canonical WNT/PCP signalling in cancer: Fzd6 takes centre stage. Oncogenesis. 2017; 6(7): e364. doi: 10.1038/oncsis.2017.69.